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Imaging Drug Uptake by Bioorthogonal Stimulated Raman 
Scattering Microscopy†  
William J. Tipping,a,b Martin Lee,b Alan Serrels,b,c Valerie G. Bruntonb,* and Alison N. Hulmea,* 
Stimulated Raman scattering (SRS) microscopy in tandem with bioorthogonal Raman labelling strategies is set to 
revolutionise the direct visualisation of intracellular drug uptake. Rational evaluation of a series of Raman-active labels has 
allowed the identification of highly active labels which have minimal perturbation on the biological efficacy of the parent 
drug. Drug uptake has been correlated with markers of cellular composition and cell cycle status, and mapped across 
intracellular structures using dual-colour and multi-modal imaging. The minimal photoxicity and low photobleaching 
associated with SRS microscopy has enabled real time imaging in live cells. These studies demonstrate the potential for SRS 
microscopy in the drug development process. 
Introduction 
Visualising the complex interplay between bioactive small 
molecules and an intricate network of cellular machinery 
represents a major challenge within chemical biology, medical 
sciences and pharmaceutical development.1-4 Improving pre-
clinical modelling studies, through integrating advanced 
imaging techniques into the early stages of drug-discovery 
campaigns, may also help reduce the high attrition rates of 
clinical drug candidates.5 Consequently, techniques which 
enable the direct visualisation of drug molecules in a non-
destructive manner, and without the use of bioorthogonal 
ligation or antibody detection, represent an attractive prospect 
for biomedical and pharmaceutical research. 
Spontaneous Raman microscopy enables the detection of 
molecular vibrations and has been applied to the direct 
visualisation of cells and their contents,6 and used for in vivo 
cancer diagnosis.7 Advances in microscope design and the 
development of stimulated Raman scattering (SRS) microscopy 
have delivered improved sensitivity, spectral resolution and 
imaging speeds.8-10 SRS allows sample visualisation and 
quantification based upon bond-specific chemical contrast, at 
up-to video-rate acquisition speeds.11 It has been widely used 
to study high-concentration species within cells, including 
protein,12-14 lipids15,16 and DNA.17,18 SRS microscopy in tandem 
with the development of Raman labelling strategies looks set to 
play an important role as a new imaging modality to significantly 
enhance drug discovery and life-sciences research.19-23  
 
Figure 1 Bioorthogonal Raman imaging approaches. (A) Raman imaging through 
metabolic incorporation of alkynes. (B) Multicolour SRS drug imaging with bioorthogonal 
(bis)alkyne labels. 
Spectroscopically bioorthogonal labelling strategies, including 
alkyne-tag Raman imaging, have been proposed as an efficient 
route to bio-molecule visualisation by Raman microscopy 
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(Figure 1).24 Alkynes, and a number of other functional groups, 
generate Raman signals within the cellular silent region 
(1800 – 2800 cm-1), making them particularly attractive as 
labels. A limited number of spectroscopically bioorthogonal 
Raman labelled species, typically with high intracellular 
concentrations, have been visualised by Raman and SRS 
microscopy.25-29 This includes EdU (Figure 1A),30 an alkyne-
containing thymidine analogue, and the clinical drug, 
Erlotinib.31 However, despite the potential which this technique 
clearly demonstrates, a unified approach to the successful 
imaging of drugs within cells using SRS microscopy is yet to be 
established. An analytical approach based on label design, 
biological validation, confirmation of cellular uptake and 
successful SRS imaging would allow SRS microscopy to be fully 
exploited in the drug development process. 
Results and discussion 
Selection of Raman labels  
Small molecule visualisation by Raman microscopy requires a 
large Raman scattering cross section with minimal perturbation 
on the structure and dynamics of the conjugated small 
molecule. Rational prediction of Raman activity could greatly 
accelerate the design of labels for use in biological systems, and 
help to overcome current detection limits for the intracellular 
visualisation of small molecules.31 Density functional theory 
(DFT) calculations at the B3LYP/6-31G(d) level of theory have 
been used to aid the identification of drug metabolites within 
cells,31 whilst ab initio calculations at the HF/6311G(d) level 
have been used to predict the polarizability of alkyne and aryl 
alkyne groups.29 These previous studies have shown that 
increased conjugation within a poly-yne chain is concomitant 
with enhanced polarizability and hence an increase in Raman 
scattering cross section.32-34 Experimentally, the introduction of 
aryl end-capping groups can also improve the stability and shelf-
life of poly-ynes.35-37 We sought to evaluate computationally a 
range of nitrile and alkynyl labels, which are both small and 
produce intense Raman bands in the cellular silent region (1800 
– 2800 cm-1),24,29 and to compare these results directly with 
experimentally determined values. 
The bioactive small molecule anisomycin (ANS, Figure 2) was 
identified as a suitable scaffold onto which spectroscopically 
bioorthogonal labels could be readily introduced with minimal 
functional perturbation,38-40 allowing direct comparison 
between predicted and experimental Raman activity (Table S1). 
To model the labels, DFT calculations using the B3LYP hybrid 
exchange-correlation functional, with the 6-31G(d,p) double-
zeta plus polarisation basis set, were used to predict the 
vibrational shift and Raman scattering activities (IRam). For 
comparison, DFT calculations were also performed on EdU, 
which has previously been successfully imaged by SRS 
microscopy.25,26 As expected, these DFT calculations predicted  
 
Figure 2. Functionalisation of the anisomycin scaffold. (A) Summary of the known SAR 
for anisomycin (ANS) in SAPK activation studies. (Pg indicates a propargyl group.) (B) 
Labelled anisomycin derivatives used in this study: N-5-Phenyl-2,4-pentadiyn-1-yl 
anisomycin (PhDY-ANS) and N-4-(4-Phenyl-1,3-butadiyn-1-yl)benzyl anisomycin (BADY-
ANS). Fold-increase vs EdU represents the increase in Raman scattering activity of the 
Raman label compared to EdU (C≡C) predicted by DFT calculation. Raman shifts of the 
solid material measured using the corresponding ∙TFA salt. 
an increase in the  Raman scattering activity as the polarizability 
of the Raman label increased (Figure S2A). A series of labelled 
anisomycin derivatives were prepared to validate these 
predictions (Scheme S1), and the spontaneous Raman spectra 
were recorded of each (Figure S3). The experimental results 
show a high level of consistency with DFT predictions (Figures 
S2B, S4) and allowed the identification of two lead compounds 
(PhDY-ANS and BADY-ANS, Figure 2) for use in this study. 
 
Assessment of Biological Activity 
Although the labels analysed by DFT generally have a much 
smaller MW than traditionally used fluorophores and thus might 
be expected to have fewer effects on drug metabolism and 
pharmacokinetic properties (DMPK),41 they may still perturb the 
function of a drug under investigation. Initial biological screens 
for activity are typically conducted in the low (1 – 25 µM) to mid 
(25 – 100 µM) micromolar range,42 which correlates with the 
higher end of drug concentration ranges for plasma and 
extracellular fluid.43 Thus we sought to validate the biological 
efficacy of our labelled anisomycin derivatives at low 
micromolar concentrations.  
Anisomycin is a potent inhibitor of protein synthesis and is 
known to activate the mitogen activated protein kinase 
pathways JNK/SAPK1 and p38/SAPK2 across a range of cell 
lines.44-46 Thus phosphorylation of JNK1/2 was used as a read-
out of the biological efficacy of anisomycin and its Raman-
labeled derivatives. Anisomycin has shown activity against a  
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Figure 3 Effects of anisomycin and Raman-labelled anisomycin derivatives, PhDY-ANS 
and BADY-ANS on the phosphorylation of JNK1/2 isoforms in SKBR3 cells. (A) SKBR3 cells 
were exposed to DMSO (lane 1); anisomycin (5 μM, lane 2; 10 μM, lane 3); PhDY-ANS (5 
μM, lane 4; 10 μM, lane 5) and BADY-ANS (5 μM, lane 6; 10 μM, lane 7). Western blot 
analysis was carried out with an antibody specific to phosphorylated JNK (pJNK1/2 at 
Thr183) and  an antibody that recognises phosphorylated and unphosphorylated JNK1/2 
equally well (JNK1/2). β-Actin was used as a loading control. (B) Quantification of the 
extent of JNK1/2 phosphorylation (pJNK1/2) in SKBR3 cells under the conditions 
described in (A). The pJNK1/2 activation levels in (A) were normalised to the pJNK1/2 
activation observed with anisomycin (10 μM, 30 min) which is expressed as 100 %. Error 
bars represent the standard deviation across n = 3 repeats. 
 
 
Figure 4 Raman spectroscopy of SKBR3 cells treated with ANS and BADY-ANS. (A) 
Representative spontaneous Raman spectrum recorded of a single fixed SKBR3 cell 
treated with (i) DMSO; (ii) ANS (10 μM, 30 min) and (iii) BADY-ANS (10 μM, 30 min). 
Raman spectra were normalised to the intensity of the peak at 1003 cm-1 (phenylalanine 
ring breathing mode), scaled between 0 – 35 000 counts and offset for clarity. The 
following peaks have been annotated: 1003 cm-1 (phenylalanine ring breathing mode); 
2219 cm-1 (C≡C, BADY-ANS); 2329 cm-1 (N2).27, 30  Raman spectra were acquired at λex = 
532 nm for 10 s using a 50× objective.  
number of breast cancer cell lines 47-49 and phosphorylation of 
JNK1/2 in mammalian SKBR3 breast cancer cells was therefore 
selected as a suitable model. Time-course studies showed that 
maximal activation of JNK1/2 in SKBR3 cells by anisomycin ANS 
was obtained at low micromolar concentrations within 30 
minutes (Figure S5A), and this activity was mirrored by all of the 
Raman-labelled derivatives (Figure S5B). Although PhDY-ANS 
and BADY-ANS gave reduced levels of activation at 5 µM they 
were both shown to be active at 10 µM (Figures 3), indicating 
that they retain biological activity at the low micromolar 
concentrations typically used in screening assays. 
 
Raman spectral analysis and SRS microscopy of anisomycin 
derivatives 
Spontaneous Raman spectroscopy can be used to determine 
drug uptake, with studies on pelleted cells providing a useful 
initial screening platform.50 The local intracellular environment 
may affect the Raman vibrational frequency associated with 
bioorthogonal peaks; thus screening by spontaneous Raman 
spectroscopy enables rapid establishment of on- and off-target 
vibrational frequencies for subsequent SRS microscopy. SKBR3 
cells were treated with the most Raman active derivative, 
BADY-ANS (10 µM, 30 min) and washed; analysis of a treated 
cell revealed a clear peak indicative of BADY-ANS at 2219 cm-1, 
which is absent in the DMSO and anisomycin treated controls 
(Figure 4). This supports both the cellular uptake of BADY-ANS, 
and that there was negligible change in the bioorthogonal 
Raman vibrational shift relative to that of the solid material (c.f. 
Table S1).  
Imaging using spontaneous Raman is time-consuming with 
typical acquisition times in excess of 30 minutes for a single cell-
mapping experiment.51 SRS offers up-to video-rate acquisition 
speeds, and hence is preferred for cellular imaging.11 In this 
study, SRS microscopy was performed on a custom-built 
microscope,52 with optimum sensitivity achieved at speeds of 
20 µs per pixel (which matches the longest time constant on the 
lock-in amplifier). This resulted in image acquisition times of less 
than 1 minute for a 1024 × 1024 frame, with pixel sizes ranging 
from 100 nm × 100 nm to 1 µm × 1 µm depending upon the field 
of view scanned. SKBR3 cells were treated with DMSO and ANS 
(10 μM, 30 min) and SRS images were acquired by tuning the 
frequency difference between the pump and Stokes lasers to be 
resonant with intracellular components including proteins (CH3, 
2953 cm-1; amide I, 1655 cm-1)53 and lipids (CH2, 2844 cm-1).54 
False colours were applied to individual Raman spectral 
frequencies to allow the differentiation of intracellular 
components (Figures 5A and 5B). This process allows cellular 
registration without the need for any additional labelling.  
SRS images can contain background signals from competing 
pump-probe processes such as cross-phase modulation, 
transient absorption and photothermal effects.55 Re-tuning the 
pump wavelength by a few nanometers allows off-resonance 
images to be acquired (at a difference of 10-20 cm-1 from the 
on-resonance image), which can be used to distinguish true SRS 
signals from these artefacts.55 Tuning to the spectroscopically 
bioorthogonal region of these cellular images (Figure 5A and 
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5B) showed there was minimal SRS signal detected at either 
2219 cm-1 (C≡C BADY-ANS on resonance) or 2243 cm-1 (cell-
silent region), indicating that any signals detected in this region 
can be assigned to the Raman-labelled species with confidence. 
Subsequently SKBR3 cells were treated with BADY-ANS (10 µM, 
30 min), washed and fixed for imaging. Tuning to the 
bioorthogonal region of the Raman spectrum enabled detection 
of BADY-ANS (alkyne, 2219 cm-1; off-resonance, 2243 cm-1) 
which distributes throughout the cytoplasm of the cell (Figure 
5C), and is especially pronounced in regions surrounding the 
nucleus.† The off-resonance image at 2243 cm-1, where no 
Raman transition occurs, demonstrates the non-resonant 
background free nature of SRS microscopy. SKBR3 cells treated 
at higher BADY-ANS concentrations (100 µM, 30 min) showed a 
similar intracellular distribution of labelled drug (Figure 5D) to 
those treated at the lower concentration. DFT calculations 
predicted that PhDY-ANS would have a reduced Raman 
scattering cross section (Table S1) and when SKBR3 cells were 
treated with PhDY-ANS at lower concentrations (10 µM, 30 
min) the labelled derivative could not be detected by SRS 
(Figure 5E). 
 
 
Figure 5 Multicolour SRS imaging of fixed SKBR3 cells treated with ANS and its derivatives. SKBR3 cells were treated with: (A) DMSO; (B) ANS (10 μM, 30 min); (C) BADY-ANS (10 μM, 
30 min); (D) BADY-ANS (100 μM, 30 min); (E) PhDY-ANS (10 μM, 30 min) and (F) PhDY-ANS (100 μM, 30 min). Images were acquired in sequence at (i) 2940 cm-1 (CH3, proteins); (ii) 
2844 cm-1 (CH2, lipids); (iii) 1655 cm-1 (amide-I, proteins); (iv) 2219 cm-1 (C≡C, PhDY-/BADY-ANS); 2243 cm-1 (cell-silent region). Images acquired at 1024 × 1024 pixels, 20 μs pixel 
dwell time with false colours applied to different detection wavenumbers. Scale bars: 10 μm. 
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However, when SKBR3 cells were treated with higher 
concentrations of PhDY-ANS (100 µM, 30 min) the expected 
cytoplasmic distribution of drug was observed (Figure 5F). 
These data suggest that the higher Raman scattering intensity 
of the BADY label, as compared to PhDY, enables detection of 
the Raman-labelled drug at lower dosing concentrations. Semi-
quantitative determination of the absolute intracellular 
concentration of BADY-ANS was achieved using a dilution series 
in DMSO. Using the standard microscope set-up and an 
acquisition speed of 20 µs per pixel, a linear relationship 
between SRS contrast and concentration was obtained (Figure 
S6); with clear contrast between on-resonance and 
off-resonance signals for BADY-ANS at 500 µM solution 
concentrations. The determination of the absolute intracellular 
concentration of BADY-ANS is difficult due to variation in the 
signal intensities both within individual cells and across a cell 
population (Figure 5). However, the images suggest that the 
local intracellular concentrations of labelled drug could be 
enriched by more than 50-fold from the dosing concentrations 
used (10 µM). These results highlight the potential that this 
method has for probing mechanistic aspects of cellular drug 
uptake.   
 
Multi-modal and dual colour imaging in live cells 
Live cell imaging of drug accumulation would enable studies 
correlating drug uptake and subcellular localisation with 
downstream phenotypic markers such as changes to cellular 
composition and cell cycle progression.56 To demonstrate the 
potential of SRS microscopy to visualise drug uptake and 
retention, time-resolved imaging of BADY-ANS uptake into live 
cells was performed. SKBR3 cells were treated with BADY-ANS 
(10 µM at t=0 min), and an on-resonance SRS image (at 
2219 cm-1) was acquired every minute at 20 µs per pixel, for 60 
minutes (Figure 6, SI Movie BADY-ANS). Intracellular BADY-ANS 
is detectable within 5 min suggesting rapid accumulation of the 
drug within cells, and it appears as locally concentrated bright 
spots within 10 min which persist through to 60 minutes.  
Off-resonance images acquired at 0 and 60 minutes suggest that 
there is no localised sample damage due to prolonged image 
acquisition under these conditions (Figure 6). Furthermore, the 
lack of any detectable signal (at 2219 cm-1)  in time-lapse images 
of ANS uptake over 60 minutes at equivalent dosing levels 
(Figure S7, SI Movie ANS) indicates that the increase in signal 
observed in Figure 6 is a direct result of BADY-ANS uptake, 
rather than the emergence of any parasitic signals. The signal 
intensity afforded by the BADY label means that SRS images can 
be acquired at much faster acquisition times if needed, and at 
speeds which are unobtainable using conventional spontaneous 
Raman spectroscopy. Images of SKBR3 cells incubated with 
BADY-ANS at the higher dosing concentration (100 µM, 20 min) 
could be obtained in under 1 s using acquisition times of 2 µs 
per pixel (512 × 512 frame, Figure S8).§ These real-time images 
highlight the applicability of Raman-labels to drug uptake 
studies and demonstrate the minimal phototoxicity resulting 
from SRS  
 
Figure 6 Time-lapse imaging of BADY-ANS uptake into live SKBR3 cells. SKBR3 cells were 
treated with BADY-ANS (10 μM at t = 0 min) and imaged at 2219 cm-1 (C≡C, BADY-ANS) 
every minute for 60 mins. Off-resonance images were acquired at 2243 cm-1 (cell-silent 
region) at t = 0 min and t = 60 min. Images were acquired at 1024 × 1024 pixels, 20 μs 
pixel dwell time with false colours applied to different detection wavenumbers. Scale 
bars: 10 μm. 
imaging conditions. They also show that in contrast to 
fluorescence microscopy, where photostability can represent a 
major experimental challenge, Raman labels show minimal 
photobleaching.57  
Using a dual colour approach, an overlay of images acquired for 
lipid CH2 (2844 cm-1) and BADY-ANS (2219 cm-1) at 30 minutes 
(Figure S9) suggests that in some cells the drug is initially 
concentrated in lipid droplets; however, a very heterogeneous 
uptake is observed across the focal field. Using a multi-modal 
approach to investigate this further, SKBR3 cells were treated 
simultaneously with BADY-ANS (10 µM, 30 min) and ER-Tracker 
Green (1 µM, 30 min), a cell-permeable fluorescent stain 
selective for the endoplasmic reticulum (Figure 7). In the 
control experiment, cells treated with the DMSO vehicle and ER 
tracker green (Figure 7A) showed no SRS signal at either 2219 
cm-1 (C≡C BADY-ANS on-resonance) or 2243 cm-1 (cell-silent 
region), indicating that there is no interference in the SRS 
images arising from the presence of the fluorophore. In the 
BADY-ANS treated cells (Figure 7B), the Raman-labelled drug is 
co-localised with ER-Tracker Green in the merged images, which 
is in agreement with its known binding to the 60S ribosomal 
subunit.44 These studies show that SRS microscopy allows rapid, 
non-destructive, high-resolution imaging of drug uptake in 
living cells which can be  
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Figure 7 Multi-modal imaging to determine the intracellular location of BADY-ANS. (A) 
SKBR3 cells were treated with DMSO and ER Tracker™ Green (1 μM, 30 min) before 
washing and fixing. SRS images were acquired at (i) 2940 cm-1 (CH3, proteins); (ii) 2844 
cm-1 (CH2, lipids); (iii) 1655 cm-1 (amide-I, proteins); (iv) 2219 cm-1 (C≡C, BADY-ANS); (v) 
2243 cm-1 (cell-silent region); (vi) Two-photon fluorescence (TPF) image acquired at 488 
nm (ER Tracker™ Green). (B) SKBR3 cells were treated with BADY-ANS (10 μM, 30 min) 
and ER Tracker™ Green (1 μM, 30 min) before washing and fixing. SRS images were 
acquired at (i) 2940 cm-1 (CH3, proteins); (ii) 2844 cm-1 (CH2, lipids); (iii) 1655 cm-1 (amide-
I, proteins); (iv) and (vii) 2219 cm-1 (C≡C, BADY-ANS); and (x) 2243 cm-1 (cell-silent 
region); (v) and (viii) TPF image acquired at 488 nm (ER Tracker™ Green); (vi) merge of 
images acquired in (iv) and (v); (ix) merge of images acquired in (vii) and (viii). SRS images 
mages acquired at 1024 × 1024 pixels, 20 μs pixel dwell time with false colours applied 
to different detection wavenumbers. TPF images λex = 860.8 nm and 1064 nm. Scale bars: 
10 μm.  
readily augmented using dual-colour and multi-modal 
approaches to follow accumulation into intracellular structures.  
Image acquisition at wavenumbers resonant with intracellular 
components allows drug-induced changes in cellular 
composition be analysed, which may help define the drug 
mechanism of action. The protein CH3 peak (2940 cm-1) has 
been used to distinguish between necrotic and healthy tissues 
and also for the detection of tumor margins.58,59 However, such 
changes in global protein content will not occur following acute 
drug administration. In contrast, the dynamic nature of lipid 
droplet assembly and disassembly,60,61 means that 
quantification of short term drug-induced changes in lipid 
droplets is possible. SKBR3 cells were treated (10 µM, 30 min) 
with either ANS or BADY-ANS and the lipid CH2 peak (2844 cm-1) 
was used to determine changes in the number of lipid droplets 
across the respective cell populations (Figure S10). There was a 
small reduction in the number of lipid droplets following 
treatment with ANS and BADY-ANS compared to DMSO 
controls, but further mechanistic studies will be required to 
determine the biological significance of these findings. That 
both ANS and BADY-ANS resulted in the same reduction in lipid 
droplet number provides further evidence that the BADY label 
does not alter the biological activity of anisomycin.  
As well as providing information about the spatial distribution 
of drug uptake, a dual-colour SRS approach might also be used 
to correlate drug uptake with markers of cell cycle progression. 
EdU (Figure 1) is a thymidine analogue widely used as a probe 
for DNA synthesis in proliferating cells through the CuAAC 
conjugation of fluorophores;62 and its detection has recently 
been achieved by Raman microscopy.30 Detection of EdU and 
BADY-ANS would demonstrate the potential application of SRS 
microscopy to this field. SKBR3 cells were serum-starved to 
synchronise the cell population in the G0 phase of the cell cycle, 
then treated with EdU (100 µM, 18 h) in serum containing 
medium to stimulate DNA synthesis, before washing and 
treatment with BADY-ANS (10 µM, 30 min). Intracellular uptake 
of both molecules was confirmed by the presence of two peaks 
(at 2120 cm-1 EdU and 2219 cm-1 BADY-ANS) in the 
spontaneous Raman spectrum of a pellet of treated cells (Figure 
S11). Multicolour SRS microscopy allowed the detection of 
intracellular protein (CH3, 2953 cm-1; amide-I, 1655 cm-1), lipid 
(CH2, 2844 cm-1), BADY-ANS (C≡C, 2219 cm-1) and EdU (C≡C, 
2120 cm-1) in a single cell (Figure 8). Remarkably, despite the 
lower Raman scattering activity afforded by the bioorthogonal 
alkyne of EdU as predicted by DFT (Figure S2A), it is possible to 
detect it by SRS microscopy. 
 
Figure 8 Dual colour alkyne-label imaging by SRS microscopy. SKBR3 cells were treated 
with EdU (100 μM, 18 h) and BADY-ANS (10 μM, 30 min), washed and fixed prior to 
imaging. SRS images acquired at (i) 2940 cm-1 (CH3, proteins); (ii) 2844 cm-1 (CH2, lipids); 
(iii) 1655 cm-1 (amide-I, proteins); (iv) 2219 cm-1 (C≡C, BADY-ANS); (v) 2120 cm-1 (C≡C, 
EdU); (vi) overlay of images acquired in (iv) and (v); (vii) 2243 cm-1 (cell-silent region); 
(viii) expanded view of image presented in (vi). Images acquired at 1024 × 1024 pixels, 
20 μs pixel dwell time with false colours applied to different detection wavenumbers. 
Scale bars: 10 μm. 
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This suggests that the high intra-nuclear concentration of EdU 
compensates for its lower Raman scattering activity, enabling 
its detection by SRS within the cell. Merging the image acquired 
for BADY-ANS (at 2219 cm-1) and EdU (at 2120 cm-1), allows 
simultaneous assessment of the intracellular drug 
concentration and cell cycle status (Figure 8). This 
demonstrates the potential of this approach for identifying drug 
dependent changes in cell cycle progression at the single cell 
level, which is an important advance in the drug development 
process.  
 
Application to the Investigation of Combination Therapies 
The use of combination therapies is an area of increasing 
interest in drug discovery;63-65 assessment of the individual 
effects of drugs (often with differential rates of uptake) on cell 
populations in combined doses represents a major challenge.66 
Here we demonstrate the power of dual colour alkyne-label 
imaging by SRS microscopy using bespoke alkyne-derived 
Raman labels as a potential solution to this challenge. 
Accumulation of a drug within cells can range from a high local 
concentration, as with EdU, to a more diffuse distribution, as 
illustrated for BADY-ANS. Since the signal intensity achieved is 
directly related to this local concentration, this is an important 
consideration in the choice of label used for Raman imaging. 
Drugs with a more diffuse distribution thus require the use of a 
higher intensity label (BADY or PhDY) to enable effective 
imaging. Selecting two appropriate Raman labels based on DFT 
predictions (Table S1) would enable rapid experimental design. 
While further label development could extend the current 
spectroscopic pallet to enable greater oportunities for multiplex 
detection in SRS imaging. 
Conclusions 
The outstanding biocompatibility of SRS microscopy is set to 
revolutionise our ability to probe intracellular biological 
processes. This study describes the rational evaluation of a 
selection of spectroscopically biorthogonal labels for SRS 
microscopy, allowing two functionally active lead derivatives 
(PhDY-ANS and BADY-ANS) to be selected for study. The 
subcellular localisation of the most Raman active derivative, 
BADY-ANS, has been determined using dual-colour and multi-
modal imaging approaches. The simultaneous detection of 
BADY-ANS together with either lipid droplets or EdU, 
demonstrates the potential of dual-colour SRS microscopy for 
identifying drug-dependent changes in cellular composition and 
cell cycle progression at the single cell level. Time resolved 
detection of the uptake of BADY-ANS into live cells highlights 
the biocompatibility of this technique. On-going improvements 
to microscope design and optics, combined with the 
development of bespoke spectroscopically bioorthogonal 
labels, ensure that the future is bright for this imaging modality. 
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Experimental 
Computational methods 
The geometries of compounds evaluated in Table S1 and Figure 
S2 were optimised at the B3LYP/6-31G(d,p) level of theory in 
the gas phase, using the Gaussian 09 programme. Vibrational 
frequencies and Raman scattering activities, obtained from the 
polarizability derivatives, were calculated analytically.  
 
Cell Culture 
Human breast cancer cell line SKBR3 was purchased from the 
American Type Culture Collection, and maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma-Aldrich) 
supplemented with 2 mM L-glutamine, 1% penicillin-
streptomycin and 10% foetal bovine serum (all Thermo Fisher 
Scientific) at 37 °C in a humidified atmosphere containing 5% 
CO2. For experiments using EdU (Thermo Fisher Scientific) cells 
grown under these normal conditions were synchronized in G0 
by serum starvation, where the 10% FBS containing medium 
was removed and cells were cultured in medium containing 
0.1% FBS for 24 h, prior to EdU treatment in 10% serum-
containing DMEM. 
 
Western Blotting 
Cells were treated with ANS (Abcam) or Raman-labelled 
derivatives as indicated in the figure legend. Cells were washed 
with ice-cold PBS and subsequently lysed in RIPA buffer 
supplemented with cOmplete ULTRA protease inhibitor and 
PhosSTOP phosphatase inhibitor cocktails (Roche). Cleared 
lysates were resolved by SDS-PAGE. Primary antibodies used for 
Western blotting were as follows: phosphoJNK1/2 
(Thr183/Tyr185; 1:1000), JNK1/2 (1:1000) and β-Actin (1:3000) 
(all Cell Signaling Technologies). 
 
Spontaneous Raman spectroscopy 
The spontaneous Raman spectra were acquired using a confocal 
Raman spectrometer (inVia Raman microscope, Renishaw) at 
room temperature. A 297 mW (206 mW after objective) 785 nm 
diode laser or a 200 mW 532 nm laser excitation source was 
used to excite the sample through a 50×, N.A. 0.75 objective 
(Leica Biosystems). The recorded spectral range for grating 1200 
g mm-1 was 100–3200 cm-1. The total data acquisition was 
performed during 60 s for spectra recorded  λex = 785 nm or 10 
s for spectra recorded at λex = 532 nm using the WiRE software. 
All of the spectra acquired at λex = 785 nm were background 
subtracted using a background correction algorithm as 
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described previously,67 whilst those acquired at λex = 532 nm are 
uncorrected.  
 
Two-photon Fluorescence and Stimulated Raman Scattering (SRS) 
Microscopy 
Images were acquired using a custom-built multi-modal 
microscope setup. A picoEmerald (APE, Berlin, Germany) laser 
provided both a tunable pump laser (720-990 nm, 7 ps, 80 MHz 
repetition rate) and a spatially and temporally overlapped 
Stokes laser (1064 nm, 5-6 ps, 80 MHz repetition rate). The 
output beams were inserted into the scanning unit of an 
Olympus FV1000MPE microscope using a series of dielectric 
mirrors and a 2× lens based beam-expanding module. The 
resulting 2.4 mm beams were expanded by a further 3.6× lens 
within the microscope and directed into an Olympus 
XLPL25XWMP N.A. 1.05 objective lens using a short-pass 
690 nm dichroic mirror (Olympus). The objective was under 
filled to achieve higher power transmissions through the 
microscope which were shown to be essential to detect the SRS 
signal. Backscattered emission signals from two-photon 
fluorescence was separated from any backscattered excitation 
light using a short-pass 690 nm dichroic mirror and IR cut filter 
(Olympus). A series of filters and dichroic mirrors were then 
used to deconvolve the different emission signals onto one of 4 
available photo-multiplier tubes (PMT). ER-Tracker Green 
twophoton fluorescence signals were filtered using FF552-Di02, 
FF483/639-Di01 and FF510/84 (Semrock).  
For SRS measurements, the Stokes beam was modulated with a 
20 MHz EoM built into the picoEmerald. Forward scattered light 
was collected by a 20× Olympus XLUMPLFLN N.A. 1.00 objective 
lens and Stokes light was removed by filtering with an 
ET890/220m filter (Chroma). A telescope focused the light onto 
an APE silicon photodiode connected to an APE lock in amplifier 
with the time constant set to 20 µs except for fast acquisitions 
where it was set to 2 µs. The lock in amplifier signal was fed into 
an Olympus FV10-Analog unit. 
Laser powers after the objective were measured up to 
40-70 mW for the pump laser and up to 70 mW for the Stokes 
laser. All images were recorded at 512 × 512 or 1024 × 1024 
pixels with a pixel dwell time between 2 and 20 μs, using 
FluoView FV10-ASW scanning software (Olympus).  
 
Sample preparation for spontaneous Raman spectroscopy 
SKBR3 cells were treated with BADY-ANS (10 μM, 30 min), ANS 
(10 μM, 30 min) or DMSO (1:1000, 30 min) and then washed 
with PBS prior to fixing with formaldehde (3.7% in PBS, 10 min, 
37 °C). The cells were washed with PBS (2×) prior to analysis of 
a single cell by spontaneous Raman spectroscopy at λex = 532 
nm. For analysis of EdU incorporation into newly-synthesised 
DNA, SKBR3 cells were serum starved for 24 h prior to treatment 
with EdU (100 μM, 18 h) in serum-containing DMEM followed 
by treatment with BADY-ANS (100 μM, 20 min), before washing 
with PBS prior to trypsinisation and diluted with DMEM. The 
resulting cell suspension was centrifuged at 175g and the cell 
pellet washed with DMEM/PBS (1/1 v/v; 10 mL) and re-
centrifuged (2×). The cell pellet was transferred to CaF2 
coverslips for analysis by spontaneous Raman spectroscopy 
using λex = 785 nm. 
 
Sample preparation for SRS Microscopy 
For all SRS imaging experiments, SKBR3 cells were first seeded 
into Fluorodish Cell Culture Dishes (World Precision 
Instruments) with a density of 1 × 105 cells/dish with 2 mL 
DMEM culture medium for 20 h. Details of the dosing 
concentrations and dosing times are provided in the figure 
legends. Where indicated, cells were fixed with formaldehyde 
(3.7% in PBS, 10 min, 37 °C) and washed with PBS (3 × 2 mL) 
before imaging. For multi-modal imaging experiments with ER-
Tracker, SKBR3 cells were treated with ER-Tracker Green 
(BODIPY® TR Glibenclamide, Thermo Fisher Scientific) (1 μM, 30 
min) and BADY-ANS (10 μM, 30 min), washed with PBS (3 × 
2 mL), fixed (3.7 % formaldehyde in PBS, 2 min, 37 °C), washed 
with PBS (3 × 2 mL; 5 min) and imaged by SRS microscopy and 
two-photon microscopy. For analysis of EdU incorporation into 
newly synthesised DNA, SKBR3 cells were serum starved for 
24 h, prior to treatment with EdU (100 μM, 18 h) in serum-
containing DMEM followed by treatment with BADY-ANS 
(10 μM, 30 min) and fixed. 
 
Image analysis 
False colour assignments, overlays and scale bars were added 
to images using ImageJ. Consistent brightness settings were 
used throughout. For the analysis of lipid droplets: a z-stack 
across a typical field of view (~40 cells, 25× objective lens) was 
acquired for each treatment condition and a maximum intensity 
projection was created (n = 9 for each condition). The number 
of lipid droplets >1 μm were counted using threshold analysis 
with the droplet_counter.jar application on ImageJ. For real-
time imaging: frames were acquired at minute intervals and 
were compiled using ImageJ using consistent brightness 
settings throughout. Movies are supplied as .avi files in the 
supplementary information. 
Notes and references 
† This is consistent with the distribution observed by fluorescence 
microscopy upon incubation of HEK-293 cells with N-linked 
dansyl-anisomycin (109 µM, 30 min): see ref. 38. 
§ Acquisition speed limited by the microscope rather than signal 
intensity. 
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